iLIVER最新文献

{"title":"Isolated intrahepatic bile duct injury secondary to blunt abdominal trauma: A case report and literature review","authors":"Shengming Zhang ,&nbsp;Yifeng He ,&nbsp;Daiwei Zhou ,&nbsp;Jianhong Jiang,&nbsp;Jianfan Wen,&nbsp;Deqin Zeng","doi":"10.1016/j.iliver.2025.100156","DOIUrl":"10.1016/j.iliver.2025.100156","url":null,"abstract":"<div><div>Closed trauma-induced extrahepatic bile duct injuries have been occasionally reported. However, isolated intrahepatic bile duct injuries are extremely rare due to the deep location of the intrahepatic bile ducts and the protection provided by surrounding vital blood vessels and organs.</div><div>We report a case of a 50-year-old female who sustained an incomplete rupture of the left hepatic bile duct following a car accident. The patient was urgently transferred to a nearby hospital for treatment after the incident. On the 15th day of hospitalization, she developed abdominal distension, nausea, indigestion, and white stool. Large volumes of dark green ascitic fluid were drained via ultrasound-guided abdominal paracentesis. The patient requested further specialized diagnosis and treatment and was subsequently transferred to our hospital. Ultimately, percutaneous transhepatic cholangiography (PTC) revealed contrast agent extravasation from the left intrahepatic bile duct, confirming a traumatic bile duct injury. The patient underwent left hemihepatectomy on the 30th day post-injury and was discharged on the 12th postoperative day following a successful recovery.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 2","pages":"Article 100156"},"PeriodicalIF":0.0,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143844726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring emerging frontiers in hepatology: iLIVER's continuing journey","authors":"Ming-Da Wang ,&nbsp;Xin-Fei Xu ,&nbsp;Lei Cai,&nbsp;Tian Yang","doi":"10.1016/j.iliver.2025.100148","DOIUrl":"10.1016/j.iliver.2025.100148","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 1","pages":"Article 100148"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143591611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contrast-enhanced US and contrast-enhanced CT for diagnosis of focal liver lesions in liver transplant recipients: A comparative study","authors":"Nong Gao ,&nbsp;Dongli Wang ,&nbsp;Xiuzhu Ma ,&nbsp;Faqin Lv ,&nbsp;Xiuyun Ren","doi":"10.1016/j.iliver.2025.100147","DOIUrl":"10.1016/j.iliver.2025.100147","url":null,"abstract":"<div><h3>Background and aims</h3><div>Contrast-enhanced ultrasound (CEUS) is widely used in the diagnosis of complications after liver transplantation. This study compared the diagnostic efficacy of CEUS with that of contrast-enhanced computed tomography (CECT) for focal liver lesions in liver transplant recipients.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed 115 liver transplant recipients who were diagnosed to have focal liver lesions at our hospital between June 2015 and June 2023. All patients were examined by CEUS and CECT and had a definitive pathological diagnosis. Based on the diagnostic outcomes, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of these imaging modalities in differentiating between benign and malignant lesions were calculated using a four-table method. Differences in diagnostic efficacy between CEUS and CECT with respect to pathological findings were compared using the chi-squared test and Fisher's exact test. The consistency of diagnosis between these modalities was assessed using the linear weighted kappa test.</div></div><div><h3>Results</h3><div>CEUS identified 79 malignant and 36 benign lesions, while CECT detected 81 malignant and 34 benign lesions. The sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy of CEUS and CECT in diagnosis of focal lesions in transplanted livers were 95.7% vs 97.2%, 97.2% vs 96.1%, 97.9% vs 97.5%, 97.2% vs 98.6%, and 96.4% vs 97.1%, respectively. Both CEUS and CECT demonstrated comparable diagnostic efficacy (κ = 0.899). CEUS showed strong diagnostic consistency with pathological results (κ = 0.912) and was more effective than CECT in diagnosing focal normal liver tissue and fat infiltration (<em>p</em> &lt; 0.05). Both methods were equally effective for diagnosis of focal inflammatory lesions, infarction, and hemangioma.</div></div><div><h3>Conclusion</h3><div>CEUS is as effective as CECT for diagnosis of benign and malignant lesions in transplanted livers but surpasses CECT in differentiating benign lesions, particularly focal normal liver tissue and fat infiltration.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 1","pages":"Article 100147"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143552499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment for unresectable hepatocellular carcinoma patients: Options and management after complete response","authors":"Jin-Ming Wang ,&nbsp;Guo-Gao Qiu ,&nbsp;Zhi-Dong Liu ,&nbsp;Jia-Yong Su ,&nbsp;Da-Long Yang ,&nbsp;Zhu-Jian Deng ,&nbsp;Zhi-Cheng Li ,&nbsp;Jian-Hong Zhong","doi":"10.1016/j.iliver.2025.100145","DOIUrl":"10.1016/j.iliver.2025.100145","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 1","pages":"Article 100145"},"PeriodicalIF":0.0,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143480325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Itaconate facilitates methane-induced Nrf2 pathway activation for mitigating liver ischemia and reperfusion injury","authors":"Tianyi Zhang ,&nbsp;Danfeng Fan ,&nbsp;Kewei Qin ,&nbsp;Hongtao Lu ,&nbsp;Linwei Zhao ,&nbsp;Kexin Liu ,&nbsp;Pei Zhang ,&nbsp;Qiang Sun ,&nbsp;Zhouheng Ye","doi":"10.1016/j.iliver.2025.100144","DOIUrl":"10.1016/j.iliver.2025.100144","url":null,"abstract":"<div><h3><em>Background and aims</em></h3><div>Methane has shown protective effects against ischemia and reperfusion injury (IRI) in the liver, but the mechanism underlying these beneficial effects is unclear. To investigate the hypothesis that itaconate facilitates in methane-induced Nrf2 pathway activation to mitigate liver IRI.</div></div><div><h3><em>Methods</em></h3><div>An oxygen and glucose derivation (OGD) model using RAW 264.7 cells and a liver IRI model in mice were established. Methane's beneficial effects were assessed through hematoxylin and eosin (HE) staining, Suzuki's score, serum alanine transferase level, superoxide dismutase (SOD) level, malondialdehyde (MDA) level, and cell viability. The relative expression levels of Nrf2, its downstream molecules and some inflammatory factors were detected via western blotting. Itaconate levels were analyzed using liquid chromatography. RAW 264.7 cells were transfected with short hairpin RNA targeting mouse aconitate decarboxylase 1 (Acod1) mRNA for itaconate downregulation.</div></div><div><h3><em>Results</em></h3><div>Methane significantly alleviated liver IRI, as shown by the significant reduction in Suzuki's scores and alanine transferase (ALT) levels in vivo. Methane treatment significantly increased MTT and SOD levels and decreased MDA levels in the OGD injury model in vitro. Methane also increased the total and nuclear Nrf2 expression levels, activated downstream molecules including heme oxygenase-1 (HO-1), NQO1 and affected the production of inflammatory cytokines such as IL-10, IL-1β, and IL-12. Itaconate levels were significantly elevated after methane treatment compared with the OGD injury group. The protective effects of methane were abolished after itaconate downregulation through <em>Acod1</em> knockdown.</div></div><div><h3><em>Conclusions</em></h3><div>Methane alleviates liver IRI through itaconate/Nrf2 pathway activation, with itaconate being critical for methane's beneficial effects.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 1","pages":"Article 100144"},"PeriodicalIF":0.0,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143487914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MAGI2-AS3/miR-450b-5p/COLEC10 interaction network: A potential therapeutic and prognostic marker in hepatocellular carcinoma","authors":"Lan-Qing Yao ,&nbsp;Yong-Kang Diao ,&nbsp;Jin-Bo Gong ,&nbsp;Li-Hui Gu ,&nbsp;Jia-Hao Xu ,&nbsp;Ming-Da Wang ,&nbsp;Chao Li","doi":"10.1016/j.iliver.2025.100146","DOIUrl":"10.1016/j.iliver.2025.100146","url":null,"abstract":"<div><h3><em>Background and aims</em></h3><div>Hepatocellular carcinoma (HCC) is a prevalent malignancy with poor prognosis. This study uses integrated bioinformatic analyses to explore potential competing endogenous RNA (ceRNA) network chains in HCC.</div></div><div><h3><em>Methods</em></h3><div>HCC expression profile data were obtained from the Gene Expression Omnibus dataset, and differential expression analysis was conducted to identify differentially expressed mRNAs (DEmRNAs), microRNAs (DEmiRNAs), and long non-coding RNAs (DElncRNAs) between HCC and normal liver tissue samples. Univariate Cox regression analysis was performed to identify mRNAs associated with the prognosis of HCC patients. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were used to classify the identified genes functionally. Cytoscape software was used to construct a protein–protein interaction network. Using the intersection method, a ceRNA network was established to align data from two databases (miRTarBase and miRcode). Pearson correlation analysis was conducted to evaluate the relationships between lncRNAs and mRNAs.</div></div><div><h3><em>Results</em></h3><div>A total of 106 prognosis-related DEmRNAs were identified between HCC and normal samples. A total of 132 DEmiRNAs and 42 DElncRNAs were dysregulated in HCC. A ceRNA network of three lncRNAs, six miRNAs, and eight mRNAs was constructed. High expression of MCM10, CDKN3, RRM2, KIF3A, and ALYREF correlated with a poor prognosis, while high expression of CPEB2, COLEC10, and PBLD was associated with a better prognosis for HCC patients. Expression analysis confirmed the differential expression of these genes in HCC samples. Correlation analysis revealed that a MAGI2-AS3/hsa-miR-450b-5p/COLEC10 axis might play a crucial role in the progression of HCC.</div></div><div><h3><em>Conclusion</em></h3><div>The ceRNA network constructed could provide insight into HCC tumorigenesis and might lead to new molecular biomarkers for diagnosing and treating HCC.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 1","pages":"Article 100146"},"PeriodicalIF":0.0,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143474184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Duodenal varices and evaluation of endoscopic cyanoacrylate injection for treatment of duodenal variceal bleeding","authors":"Jin-dong Chu ,&nbsp;Qian Bi ,&nbsp;Yan-ling Wang,&nbsp;Xue-mei Ma,&nbsp;Bo Liu,&nbsp;Liang Wu,&nbsp;Shuai Wang,&nbsp;Li-jun Shen,&nbsp;Xiao-bao Qi,&nbsp;Zheng Lu","doi":"10.1016/j.iliver.2025.100143","DOIUrl":"10.1016/j.iliver.2025.100143","url":null,"abstract":"<div><h3>Background and aims</h3><div>Duodenal varices (DVs) are a rare complication of portal hypertension. This study analyzed the clinical characteristics of DVs and examined the efficacy of endoscopic cyanoacrylate injection for duodenal variceal bleeding.</div></div><div><h3>Methods</h3><div>The clinical data of patients with DVs treated in our hospital from March 2013 to May 2024 were retrospectively analyzed.</div></div><div><h3>Results</h3><div>During the study period, 80,850 patients underwent gastroscopy for a total of 122,040 endoscopy sessions. DVs were diagnosed in 52 patients. Eight patients with DVs exhibited duodenal variceal bleeding (15.4%). The overall prevalence of DVs was 0.08%.The prevalence of DVs among patients with upper gastrointestinal varices was 0.16%. The most common etiology of DVs was liver cirrhosis (92.3%). DVs location was the descending segment of the duodenum in 34 patients (65.4%). Forty-four patients (84.6%) had concomitant esophageal and gastric varices. Successful hemostasis was achieved at the time of endoscopy in all patients undergoing emergency endoscopic treatment using cyanoacrylate injection. The 6-week mortality rate was 12.5%. The rebleeding rate was 12.5%.</div></div><div><h3>Conclusions</h3><div>DVs are uncommon, even in hospitals where liver disease is prevalent. Emergency endoscopic cyanoacrylate embolization appears to be highly effective. Complete vein embolization may be considered for patients in poor condition. Age &gt;65 years and low hemoglobin concentration are predictors of duodenal variceal bleeding.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 1","pages":"Article 100143"},"PeriodicalIF":0.0,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143348745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of metabolic signatures implicated in the progression from hepatitis to cirrhosis to hepatocellular carcinoma","authors":"Simiao Yu ,&nbsp;Sici Wang ,&nbsp;Jiahui Li ,&nbsp;Haocheng Zheng ,&nbsp;Ping Li ,&nbsp;Wenya Rong ,&nbsp;Jing Jing ,&nbsp;Tingting He ,&nbsp;Yongqiang Sun ,&nbsp;Liping Wang ,&nbsp;Zhenyu Zhu ,&nbsp;Xia Ding ,&nbsp;Ruilin Wang","doi":"10.1016/j.iliver.2024.100142","DOIUrl":"10.1016/j.iliver.2024.100142","url":null,"abstract":"<div><h3>Background and aims</h3><div>Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. The mechanisms driving the transition from hepatitis to cirrhosis, and eventually, to HCC are unclear. This study aimed to clarify the metabolic changes that underly the progression of HCC and identify potential prognostic and therapeutic biomarkers.</div></div><div><h3>Methods</h3><div>This prospective study collected serum samples from patients with chronic hepatitis, cirrhosis, or HCC, hospitalized at the Fifth Medical Center of the PLA General Hospital, from December 2022 to December 2023. The samples were analyzed using non-targeted, ultra-high-performance liquid chromatography and mass spectrometry. Partial least squares-discriminant analysis modeling and <em>t</em>-tests were used to identify key differentially expressed metabolites associated with the progression from hepatitis to cirrhosis to HCC. Pathway enrichment analysis was conducted to determine the key metabolic pathways involved, while machine learning models were applied to identify the metabolite signatures.</div></div><div><h3>Results</h3><div>We identified 153 differentially expressed metabolites in the progression from hepatitis to cirrhosis to HCC, many of which were involved in ammonia cycling or the metabolism of methylhistidine, alanine, arginine, proline, or betaine. We also identified L-histidine and adenosine as the metabolites that demonstrated significant sensitivity and specificity for distinguishing among the hepatitis, cirrhosis, and HCC stages.</div></div><div><h3>Conclusions</h3><div>Our study comprehensively characterized the metabolic profiles of the different stages of the hepatitis-cirrhosis-HCC transition. We showed that serum metabolite detection is a viable diagnostic tool for identifying and monitoring high-risk individuals, which could potentially be used to halt the development of HCC.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 1","pages":"Article 100142"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143129055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging role of natural bioactive compounds in navigating the future of liver disease","authors":"Neha Chaudhary ,&nbsp;Muhammad Arif ,&nbsp;Sheeba Shafi ,&nbsp;Shom Prakash Kushwaha ,&nbsp;Pushpendra Soni","doi":"10.1016/j.iliver.2024.100140","DOIUrl":"10.1016/j.iliver.2024.100140","url":null,"abstract":"<div><div>Liver diseases, including liver inflammation, fatty liver disease, cirrhosis, and hepatocellular carcinoma, represent significant global health challenges. Traditional treatments often emphasize symptom management, leading to increased interest in natural bioactive compounds for their potential therapeutic benefits. This review examines the role of natural bioactive compounds in managing hepatic disorders, with a particular focus on their mechanisms of action and supporting clinical evidence. Compounds such as curcumin, silymarin, resveratrol, triterpenoids, apigenin, and delphinidin derivatives have demonstrated promising hepatoprotective effects in preclinical studies, largely due to their anti-inflammatory, antioxidant, and anti-fibrotic properties. Nevertheless, further research is necessary to determine optimal dosing, safety profiles, and long-term effects. Understanding the mechanisms of action and therapeutic potential of these bioactive compounds may provide critical insights into their role in the treatment of hepatic diseases.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 1","pages":"Article 100140"},"PeriodicalIF":0.0,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143129056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WGCNA combined with machine learning to explore potential biomarkers and treatment strategies for acute liver failure, with experimental validation","authors":"Xinyan Wu ,&nbsp;Xiaomei Zheng ,&nbsp;Gang Ye","doi":"10.1016/j.iliver.2024.100133","DOIUrl":"10.1016/j.iliver.2024.100133","url":null,"abstract":"<div><h3>Background and aims</h3><div>To identify biomarkers to predict acute liver failure and investigate the mechanisms and immune-related pathways linked to its onset and progression.</div></div><div><h3><em>Methods</em></h3><div>We analyzed gene expression differences between patients with acute liver failure (ALF) and controls in the GSE14668 dataset. Clinically relevant modules and key ALF-associated genes were identified using weighted gene co-expression network analysis (WGCNA) in conjunction with differential gene expression (DEG) analysis. Enrichment analysis was carried out and protein–protein interaction networks were constructed to understand the functions and pathways. Six potential diagnostic biomarkers were identified using machine learning algorithms. Diagnostic performance was assessed via column charts and area under the curve calculations. Single-sample gene set enrichment analysis evaluated the relationship between known marker gene sets and potential biomarker expression. We also examined diagnostic biomarker mRNA levels in ALF models <em>in vivo</em> and <em>in vitro</em>. We estimated the relative infiltration levels of 22 immune cell subpopulations in ALF samples, and explored the link between diagnostic biomarkers and infiltrating immune cells.</div></div><div><h3><em>Result</em></h3><div>We found 352 DEGs associated with ALF. WGCNA analysis and intersecting DEGs identified 191 significant ALF-related genes. Machine learning identified <em>HORMAD2</em>, <em>WNT10A</em>, <em>ATP6V1E2</em>, <em>CMBL</em>, <em>ARRDC4</em>, and <em>LPIN2</em> as potential diagnostic biomarkers. Cell experiments and quantitative real-time polymerase chain reaction supported the therapeutic potential of eriodictyol for ALF. Immune infiltration analysis suggested that plasma cells, CD4 memory resting and activated T cells, macrophages, and neutrophils might play roles in the progression of ALF.</div></div><div><h3><em>Conclusion</em></h3><div>We identified <em>HORMAD2</em>, <em>WNT10A</em>, <em>ATP6V1E2</em>, <em>CMBL</em>, <em>ARRDC4</em>, and <em>LPIN2</em>, as diagnostic biomarkers for ALF and demonstrated the effectiveness of eriodictyol for treating ALF. Immune cell infiltration may play a significant role in the pathogenesis and progression of ALF.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100133"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}